7-{8-[(2,2-Dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid | 1394115-93-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 7-{8-[(2,2-Dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid
• 英文别名: 7-[8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
• CAS: 1394115-93-5
• 化学式: C₂₅H₄₀O₆
• 分子量: 436.6
• InChiKey: XWLXKKNPFMNSFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• METHODS FOR PREPARING STATIN COMPOUNDS BY LACTONIZATION
  申请人：Ma Deyin

  公开号：US20120296099A1

  公开（公告）日：2012-11-22

  A method for preparing a statin compound by lactonization is disclosed, which comprises the following step: lactonizing a compound of formula II into the compound of formula I in the presence of a strong acid catalyst and a dehydrant in a first solvent, wherein Z represents H, ammonium, or a metal cations; R 1 is H or C 1 -C 6 alkyl, preferably H or CH 3 , R 2 is CH 3 , OH, CH 2 OH, CH 2 OC(O)R 3 , CH 2 OR 3 , or COOR 4 , preferably CH 3 or OH, R 3 and R 4 are independently selected from the group consisting of H and C 1 -C 6 alkyl.

  揭示了一种通过内酯化制备他汀类化合物的方法，包括以下步骤：在第一溶剂中，在强酸催化剂和脱水剂的存在下，将化合物II内酯化为化合物I，其中Z代表H、铵离子或金属阳离子；R1为H或C1-C6烷基，优选H或CH3；R2为CH3、OH、CH2OH、CH2OC(O)R3、CH2OR3或COOR4，优选CH3或OH；R3和R4分别独立地选自H和C1-C6烷基的群。
• Lipid regulating compositions
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0276807A2

  公开（公告）日：1988-08-03

  Single dose formulations containing 5-(2,5-­dimethylphenoxy)-2,2-dimethylpentanoic acid and an HMG-CoA reductase inhibitor are effective phar­macological formulations for regulating blood serum lipid and cholesterol levels.

  含有 5-(2,5-二甲基苯氧基)-2,2-二甲基戊酸和 HMG-CoA 还原酶抑制剂的单剂量制剂是调节血清脂质和胆固醇水平的有效药理制剂。
• Prevention and/or treatment of ischemia/reperfusion injury
  申请人：Consorci Institut Catala de Ciencies Cardiovasculars

  公开号：EP2949324A1

  公开（公告）日：2015-12-02

  The present invention relates to compounds for their use in the prevention and/or treatment of ischemia/reperfusion injury of a tissue or an organ in a subject, wherein said compounds are statins, statin derivatives, agents inhibiting RhoA translocation to the cell membrane, agents increasing PKCε activity or any combination thereof, administered to the subject in need thereof prior to reperfusion.

  本发明涉及用于预防和/或治疗受试者组织或器官缺血/再灌注损伤的化合物，其中所述化合物为他汀类药物、他汀类药物衍生物、抑制 RhoA 转位至细胞膜的制剂、增加 PKCε 活性的制剂或其任意组合，在再灌注前施用给需要的受试者。
• SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
  申请人：Schering Corporation

  公开号：EP1601668B1

  公开（公告）日：2008-08-27
• METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL
  申请人：Aegerion Pharmaceuticals

  公开号：EP1945205A2

  公开（公告）日：2008-07-23